1. Home
  2. EYEN vs MIST Comparison

EYEN vs MIST Comparison

Compare EYEN & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EYEN
  • MIST
  • Stock Information
  • Founded
  • EYEN 2014
  • MIST 2003
  • Country
  • EYEN United States
  • MIST Canada
  • Employees
  • EYEN N/A
  • MIST N/A
  • Industry
  • EYEN Biotechnology: Pharmaceutical Preparations
  • MIST Biotechnology: Pharmaceutical Preparations
  • Sector
  • EYEN Health Care
  • MIST Health Care
  • Exchange
  • EYEN Nasdaq
  • MIST Nasdaq
  • Market Cap
  • EYEN 38.2M
  • MIST 81.5M
  • IPO Year
  • EYEN 2018
  • MIST N/A
  • Fundamental
  • Price
  • EYEN $0.55
  • MIST $1.44
  • Analyst Decision
  • EYEN Strong Buy
  • MIST Strong Buy
  • Analyst Count
  • EYEN 2
  • MIST 3
  • Target Price
  • EYEN $12.00
  • MIST $13.00
  • AVG Volume (30 Days)
  • EYEN 879.0K
  • MIST 177.8K
  • Earning Date
  • EYEN 11-11-2024
  • MIST 11-11-2024
  • Dividend Yield
  • EYEN N/A
  • MIST N/A
  • EPS Growth
  • EYEN N/A
  • MIST N/A
  • EPS
  • EYEN N/A
  • MIST N/A
  • Revenue
  • EYEN $31,405.00
  • MIST N/A
  • Revenue This Year
  • EYEN $50,309.30
  • MIST N/A
  • Revenue Next Year
  • EYEN $421.63
  • MIST N/A
  • P/E Ratio
  • EYEN N/A
  • MIST N/A
  • Revenue Growth
  • EYEN N/A
  • MIST N/A
  • 52 Week Low
  • EYEN $0.37
  • MIST $1.12
  • 52 Week High
  • EYEN $2.57
  • MIST $3.52
  • Technical
  • Relative Strength Index (RSI)
  • EYEN 52.60
  • MIST 42.50
  • Support Level
  • EYEN $0.52
  • MIST $1.41
  • Resistance Level
  • EYEN $0.59
  • MIST $1.53
  • Average True Range (ATR)
  • EYEN 0.05
  • MIST 0.07
  • MACD
  • EYEN 0.01
  • MIST -0.01
  • Stochastic Oscillator
  • EYEN 66.45
  • MIST 26.96

About EYEN Eyenovia Inc.

Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.

About MIST Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).

Share on Social Networks: